---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056890"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:33:53.209849+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Equillium Q1 revenue $10.7M, net loss $2.7M; positive lupus data, milestones ahead

## Summary
- Revenue of $10.7M, up from $8.9M YoY, all from Ono partnership (development funding and amortization).
- Net loss narrowed to $2.7M ($0.08 loss per share) vs $3.9M ($0.11) in Q1 2023.
- Cash, cash equivalents and short-term investments $32.3M as of March 31, 2024; runway into 2H 2025.
- Positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis announced in early April.
- Upcoming: EQ101 Phase 2 alopecia areata topline data Q2 2024; EQUATOR interim review Q3 2024; Ono option exercise decision 2H 2024 (potential ~$32M payment).

## SEC filing metadata
- accession: 0000950170-24-056890
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/0000950170-24-056890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/eq-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056890
- JSON: https://secwatch.observer/filing/0000950170-24-056890.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056890.txt

## Key facts
- Earnings Releases
  Equillium, Inc. reported the first quarter ended March 31, 2024 results: revenue $10.7 million, net income $2.7 million, EPS $(0.08) per basic and diluted share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $10.7 million
  - Net income: $2.7 million
  - EPS: $(0.08) per basic and diluted share
  - Result: reported results
  source text: 1 Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time of payment. Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023. Revenue in the first quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000095017024056890/0000950170-24-056890-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.